We would love to hear your thoughts about our site and services, please take our survey here.
Redom will enable the payment of dividends in Q3. after the NSD share problem of the Russian shareholders are sorted out. Company split if it happens after 75% shareholders approval will only happen in Q12024. Hope calm will return to the market tomorrow
I was at the investor meeting this afternoon, when split into 2 legal entities happens, existing shareholders will get shares in these 2 companies as GDR which will be traded at the LSE. Don’t see why people are panicking.
With year end inventory of 336 koz at gold price of $1900, it is worth $630 million. Debt should be down to 2B at end of Q1.
On Amazon, there is a Strep A test kit called GIMA, a box of 20 for £54 to be delivered around 22 Dec. This is the only 1 available. Novacyt should go to all high street pharmacies to sell their LF test kits as well as going online with Amazon.
Tata MD can achieve its aim to be a global leader in diagnostic by buying a substantial stake in NCYT, say 26% without the need to acquire 100%. Then work with Bio who could by then acquire, say 25% of NCYT. Together both Bio and Tata will have at least 51% to gain management control of NCYT. Tata will have access to the IPs and products of both Bio and NCYT, killing 2 birds with one stone. A cheap and fast way for Tata to become a global diagnostic company. Imo, Tata might be talking to Bio behind the scene to work together for a win win relationship to take advantage of the current low SP of NCYT.
I think DA is probably trimming some fats out of the too heavy senior management. There are overlapping roles among Paul Eros, Anthony Dyer, Claire Monk and Arjan. Too many cooks spoil the broth as the saying goes.
To be a multi billion diagnostics and testings global powerhouse better than Eurofins in size and profitability, NCYT has been building up their R&D and top level management team by recruiting the best from Roche, Abbott etc. With the arrival of DA, I would expect the company to go on an aggressive acquisition drive and take on some debts to finance these acquisitions. We should not expect any dividends or shares buyback if we are really LTH, instead we should sit back and enjoy the ride to becoming a global D&T company within the next 5 years.
Eurofins started life with 4 employees in 1987 and went public with IPO in 1997 with 100 employees. Now Eurofins has 50,000 employees in over 50 countries and 800 laboratories. I don’t have to list here their achievements in revenue and market cap over the years. Their track records are available on the internet. I think the BOD of NCYT is trying to replicate the path of Eurofins with the recruitments of very experienced and capable industry professionals in the last 18 months. We as LTH should be more patient and not look at the daily SP and ***** about the short term SP performance. Let’s give the professionals in NCYT the space and support to transform it to be a global diagnostic and testing power house based in the U.K..
Dispute is on the Q4 deliveries of £129 million of a product which NCYT has made a product warranty cost of £20 million assuming that DHSC would accept these products to be replace. I suspect DHSC is asking NCYT to cancel the Q4 purchase and the 2021Q1 purchase of £40 million for the full credit note of the whole amount of £169 million, 129+40. Is DHSC trying to renege on the contract it awarded to NCYT with unjustified product performance claim?
DHSC dispute is on a product supplied in the first contract and NCYT has taken a product warranty provision of nearly £20 million in the 2020 accounts as they believe that in the worse case, the company will provide replacement products with sales value of around £100 million, 80% Gross margin, with raw material cost of £20 million which is the warranty provision. If DHSC were to accept replacement product, then the case is settled and all delayed receivables should be paid to NCYT.
Top 10% shareholders account for only 6.38% in NCYT. Since the fundamentals of the company are very good, why are the professional investment companies not interested? Retail or individual investors are too sensitive to any bad news and are not LTH.
I am surprised to see that the 10th largest shareholder of NCYT has only 84,018 shares as shown by the MarketScreener website. Could any one please clarify whether this information is correct? I am sure some members of this BB chat group have more shares than 80,000.